5-HT1A receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: Bridging the gap between serotonergic and glutamatergic mechanisms
P Huot, JM Brotchie - Experimental neurology, 2011 - Elsevier
In a recent issue of Experimental Neurology, Dupre et al. report on a study performed in the
6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson's disease (PD) which brings …
6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson's disease (PD) which brings …
MDMA and fenfluramine reduce L‐DOPA‐induced dyskinesia via indirect 5‐HT1A receptor stimulation
C Bishop, JL Taylor, DM Kuhn… - European Journal of …, 2006 - Wiley Online Library
Abstract Chronic l‐3, 4‐dihydroxyphenylalanine (L‐DOPA) pharmacotherapy in Parkinson's
disease is often accompanied by the development of abnormal and excessive movements …
disease is often accompanied by the development of abnormal and excessive movements …
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …
Parkinson's disease patients and represents a major limitation for the pharmacological …
5-HT1A agonists and dyskinesia in Parkinson's disease: a pharmacological perspective
P Huot - Neurodegenerative Disease Management, 2018 - Taylor & Francis
Activation of 5-HT1A receptors is a potential approach to reduce L-3, 4-
dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in Parkinson's disease (PD) …
dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in Parkinson's disease (PD) …
Characterizing the differential roles of striatal 5-HT1A auto-and hetero-receptors in the reduction of l-DOPA-induced dyskinesia
Abstract l-DOPA remains the benchmark treatment for Parkinson's disease (PD) motor
symptoms, but chronic use leads to l-DOPA-induced dyskinesia (LID). The serotonin (5-HT) …
symptoms, but chronic use leads to l-DOPA-induced dyskinesia (LID). The serotonin (5-HT) …
5-HT1 receptor agonists for the treatment of l-DOPA-induced dyskinesia: from animal models to clinical investigation
E Tronci, M Carta - Basal Ganglia, 2013 - Elsevier
Appearance of dyskinesia represents the most problematic side effect during chronic L-
DOPA treatment in parkinsonian patients, with serious consequences for the patient's quality …
DOPA treatment in parkinsonian patients, with serious consequences for the patient's quality …
Brain 5‐HT2A receptors in MPTP monkeys and levodopa‐induced dyskinesias
G Riahi, M Morissette, M Parent… - European Journal of …, 2011 - Wiley Online Library
Levodopa‐induced dyskinesias (LIDs) are abnormal involuntary movements induced by the
chronic use of levodopa (l‐Dopa) limiting the quality of life of Parkinson's disease (PD) …
chronic use of levodopa (l‐Dopa) limiting the quality of life of Parkinson's disease (PD) …
[HTML][HTML] 5-HT4R agonism reduces L-DOPA-induced dyskinesia via striatopallidal neurons in unilaterally 6-OHDA lesioned mice
D Ballardin, L Makrini-Maleville, A Seper… - Neurobiology of …, 2024 - Elsevier
Parkinson's disease is caused by a selective vulnerability and cell loss of dopaminergic
neurons of the Substantia Nigra pars compacta and, consequently, striatal dopamine …
neurons of the Substantia Nigra pars compacta and, consequently, striatal dopamine …
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms
V Ghiglieri, D Mineo, A Vannelli, F Cacace… - Neurobiology of …, 2016 - Elsevier
ABSTRACT L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias (LIDs) represent
the main side effect of Parkinson's Disease (PD) therapy. Among the various …
the main side effect of Parkinson's Disease (PD) therapy. Among the various …
Effect of selective and non-selective serotonin receptor activation on l-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats
E Tronci, C Fidalgo, R Stancampiano… - Behavioural Brain …, 2015 - Elsevier
Selective activation of 5-HT1 receptors has been shown to produce near to full suppression
of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease; however, a …
of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease; however, a …